Biodel

Biodel plans insulin trials

Wednesday, March 16, 2011

Biodel has selected two new formulations of recombinant human insulin for clinical testing and is accelerating clinical development plans of these mealtime insulin drug candidates.  The new formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed meal time insulin analogs while maintaining an injection site tolerability profile comparable to currently marketed insulins.  Biodel plans to test these formulations in a phase I clinical trial of approximately 18 patients with Type I diabetes.

[Read More]